Dermatologic side effects associated with the epidermal growth factor receptor inhibitors Journal Article
| Authors: | Agero, A. L. C.; Dusza, S. W.; Benvenuto-Andrade, C.; Busam, K. J.; Myskowski, P.; Halpern, A. C. |
| Article Title: | Dermatologic side effects associated with the epidermal growth factor receptor inhibitors |
| Abstract: | Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for patients with colorectal and non-small cell lung cancer refractory or intolerant to chemotherapy. Our aim was to describe key clinical features of common dermatologic adverse reactions among EGFR inhibitors, focusing mainly on skin toxicity, as well as to discuss the pathology, possible causes, and suggested treatments for these reactions. The most commonly encountered adverse effect was a mild skin toxicity characterized by a sterile follicular and pustular rash that may be treated empirically and usually does not require treatment modification. Although the precise mechanism for development of rash is not well defined, it is related to inhibition of EGFR-signaling pathways in the skin, and may serve as visible markers of anti-tumor activity and therapeutic efficacy. Secondary adverse reactions seen with anti-EGFR therapy include xerosis, pruritus, paronychia, hair abnormality, and mucositis. © 2006 American Academy of Dermatology, Inc. |
| Keywords: | epidermal growth factor; unclassified drug; clinical feature; clinical trial; histopathology; review; squamous cell carcinoma; erlotinib; drug efficacy; nonhuman; side effect; skin toxicity; skin manifestation; paclitaxel; pancreas cancer; chemotherapy; carboplatin; unindexed drug; lung non small cell cancer; mucosa inflammation; stomatitis; epidermal growth factor receptor; steroid; antineoplastic activity; cetuximab; docetaxel; irinotecan; monoclonal antibody; panitumumab; protein tyrosine kinase inhibitor; colorectal carcinoma; flushing; nail disease; pruritus; rash; maculopapular rash; lung small cell cancer; antibodies, monoclonal; head and neck cancer; acne; rosacea; gefitinib; erythema; hyperpigmentation; hair disease; platinum; hydrocortisone; dry skin; quinazolines; tetracycline; minocycline; anaphylaxis; retinoic acid; lapatinib; allergic reaction; hypersensitivity reaction; urticaria; skin infection; mucosal disease; vascular disease; epidermal growth factor receptor kinase inhibitor; drug eruptions; desquamation; paronychia; skin fissure; xerosis; erythromycin; pimecrolimus; matuzumab; pustule; clindamycin; aphthous ulcer; petechia; epidermoid cyst; canertinib; nimotuzumab; pelitinib; triamcinolone acetonide; folliculitis; betamethasone dipropionate; 6 (4 hydroxyphenyl) 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidine; cimazumab; fusidic acid; monoclonal antibody r3; acne vulgaris; leukocytoclastic vasculitis |
| Journal Title: | Journal of the American Academy of Dermatology |
| Volume: | 55 |
| Issue: | 4 |
| ISSN: | 0190-9622 |
| Publisher: | Mosby Elsevier |
| Date Published: | 2006-10-01 |
| Start Page: | 657 |
| End Page: | 670 |
| Language: | English |
| DOI: | 10.1016/j.jaad.2005.10.010 |
| PUBMED: | 17010747 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 163" - "Export Date: 4 June 2012" - "CODEN: JAADD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work